Evolution of autoantibody responses in individuals at risk of rheumatoid arthritis

Falkenburg, Willem J.J.; Schaardenburg, Dirkjan van

doi:10.1016/j.berh.2017.07.005

Cited by 13 publications

(10 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is now well-established that autoantibodies precede the onset of clinical symptoms by several years in a proportion of patients with RA (45, 46). The autoantibody response significantly evolves in the pre-clinical phase of the disease, with level increase, epitope spreading, isotype switching, affinity maturation, and change in glycosylation over time (47). Although the precise dynamics of such changes are not properly defined, and are likely to vary among different subjects, there is evidence that the extent of the autoantibody response conditions some clinical characteristics also in the very early phases of RA.…”

Section: Autoantibodies and Clinical Phenotypementioning

confidence: 99%

The Clinical Value of Autoantibodies in Rheumatoid Arthritis

et al. 2018

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a highly heterogeneous syndrome in terms of clinical presentation, progression, and response to therapy. In such a complicated context, the identification of disease-related biomarkers would be undoubtedly helpful in assisting tailored approaches for every patient. Despite remarkable efforts, however, progress in new biomarker development and validation is dramatically slow. At present, none of the candidate genetic, cellular, or molecular biomarker has yet surpassed the clinical value of RA-specific autoantibodies, including rheumatoid factor (RF) and anti-citrullinated protein autoantibodies (ACPA). Rather, recent years have witnessed significant advancements in our understanding of the multiple roles that RF and ACPA play in RA pathophysiology. This has helped clarifying the mechanistic basis of the clinical associations of autoantibodies in RA. In this short review, we will briefly summarize the effector functions of RF and ACPA, and analyse how autoantibodies may help subclassifying RA patients in terms of clinical presentation and response to therapy.

show abstract

Section: Autoantibodies and Clinical Phenotypementioning

confidence: 99%

The Clinical Value of Autoantibodies in Rheumatoid Arthritis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that lysine residues, and not arginine as in the citrullination reaction, are subject to carbamylation, whereas the obtained amino acid is homocitrulline, which is very similar to citrulline [9,[22][23].…”

Section: Antibodies Against Carbamylated Proteins (Anti-carp)mentioning

confidence: 99%

“…Many studies indicate a high predictive value for the identification of patients in pre-clinical RA, who will develop a disease in the future, because the appearance of anti-CCP may precede the first clinical symptoms. Studies show that the risk of developing RA is higher in individuals in whom anti-CCP was detected [9]. In addition, the low level of anti-CCP is a predictor of a good response to the treatment in patients with early RA [15].…”

Section: Rheumatoid Factormentioning

confidence: 99%

“…The highest level of RF IgM is detected in RA patients; therefore, the determination of RF in RA has a certain prognostic value [9]. Seropositive RA is usually characterised by a more severe course of the disease, faster destruction of joint tissues, and a greater inclination to extra-articular lesions compared to seronegative RA.…”

Section: Rheumatoid Factormentioning

confidence: 99%

“…The prevalence of autoantibodies is found in the majority of RA patients [9]. Therefore, the basis for the immunodiagnostics of rheumatic diseases are currently serological tests in which antibodies are detected.…”

Section: Serological Diagnosticsmentioning

confidence: 99%

See 2 more Smart Citations